JPH06247864A - Anti-periodontal disease agent - Google Patents

Abstract

PURPOSE:To obtain an anti-periodontal disease agent derived from a natural plant. CONSTITUTION:This anti-periodontal disease agent comprises an essence extracted from one or more galenical medicines selected from Amomum xanthioides Wall at Bark, Alpinia oxyphylla Miq, Valeriana fauriei Briq., lavender oil, rosemary oil and spike lavender oil.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to an anti-periodontal disease drug used for the prevention and treatment of periodontal diseases.

[0002]

2. Description of the Related Art Periodontal diseases except traumatic ones cause some microorganisms to adhere to and settle on teeth and periodontal tissues, and the periodontal tissues are destroyed by enzymes and endotoxins produced by those teeth. It is believed that this is a factor.

[0003] In the lesions of periodontal disease patients, Bacteroides (Bacteroides) bacterial group, full zone Agrobacterium null clay Tam
( Fusobacterium nucleatum ) and other Gram-negative obligate anaerobic bacilli have been found to proliferate, and it is well established that these bacteria are deeply involved in the onset and progression of periodontal disease. Therefore, in order to prevent and improve periodontal disease, it is important to suppress the growth of these causative bacteria, and the development of effective antibacterial active substances is desired.

Conventionally, as a method for preventing or improving periodontal disease, a method of sterilizing periodontopathic bacteria with an antibiotic,
A method using chlorhexidine or cetylpyridinium as a synthetic antibacterial agent has been proposed. However, it is pointed out that the method using antibiotics is not only effective against gram-negative bacteria, but also has been pointed out that it may cause side effects and may disturb the normal bacterial flora in the oral cavity, resulting in "bacterial metastasis". It is hard to say that it is effective, and its safety is a problem.
Therefore, it is desirable that the antibacterial active substance is a natural product that is considered to be relatively safe.

[0005]

DISCLOSURE OF THE INVENTION The present invention is an anti-periodontal disease-causing agent of natural plant origin, which prevents periodontal disease by acting on periodontal disease-causing bacteria present in the oral cavity and suppressing growth. Improved,
The goal is to be highly safe.

[0006]

Means for Solving the Problems As a result of various investigations by the present inventors in order to achieve the above-mentioned object, an extract of a certain herbal medicine effectively suppresses the growth of bacteria causing periodontal disease. The present invention has been completed and the present invention has been completed. That is, the present invention is an anti-periodontal disease agent consisting of a crude drug extract obtained from one or more crude drugs selected from the group consisting of compressed sand, valerian root, lavender oil, rosemary oil, and spike lavender oil. I will provide a.

Further, the present inventors have found that the pharmacologically active ingredient in the above crude drug extract is borneol. That is, the present invention provides an anti-periodontal disease drug containing borneol as an active ingredient. In the present specification, the "extracted extract" means
It is an extract such as a soft extract, a flow extract or a tincture, and is prepared by a usual method in accordance with the "12th Revised Japanese Pharmacopoeia" General Rules for Preparations ". For example, the method for preparing a soft extract is exemplified below. The crude drug is impregnated in the extraction solvent and filtered to obtain a filtrate. The above residue is subjected to cold soaking and filtration 2-3 times. The obtained filtrates are combined, the extraction solvent is distilled off, and concentrated to obtain an extract. In addition, it is preferable to occasionally stir during cold immersion.

As a solvent used for extraction, besides ethanol, a lower alcohol (eg, methanol, butanol,
Isopropyl alcohol) or a mixed liquid of these and water can be used. Reduced sand used in the present invention ( Amomum
xanthioides Wallich; ginger family) has an oil content of 2V / W
% Or more is used. Valeriana faurici
For Briquet, the oil production content is 0.6 V / W% or more. Lavender oil, rosemary oil and spine lavender oil may be crude or refined oils obtained from those plants.

The present inventors have found that the pharmacologically active ingredient in the above extract is d-borneol. Borneol includes d-form, l-form and dl-form, and the d-form is preferred. As d-borneol, commercially available products can be used. d-borneol has the formula:

[0010]

[Chemical 1]

## STR1 ## By the way, d-borneol (FIG. 1) is a crystalline substance obtained from the essential oil of Dryobalanops camphora (Dipterocarpaceae).
It is also contained in essential oils of natural plants such as valerian root, lavender oil, rosemary oil, and spike lavender oil. Famous as a fragrance for a long time, cosmetics,
It has been used as a raw material for the preparation of food flavors. In Chinese medicine,
It is used for the purpose of anti-inflammatory and analgesia, and is contained in many Kampo medicines, but its antibacterial activity is unknown.

[0012] The d-borneol and the crude drug extract can be used as they are or after being appropriately diluted, but they are formulated into a suitable oral composition form in terms of reachability to tissues and persistence. It can also be used. The blending amount is preferably 0.01 to 10% by weight, and more preferably 0.1 to 5% by weight based on the whole composition. The pharmaceutical agent of the present invention may be used as an oral pharmaceutical composition in combination with conventional pharmaceutical auxiliary agents. Examples of the form of such an oral pharmaceutical composition include solid preparations such as tablets, granules, capsules and liquid preparations. Solid formulation is a conventional excipient
(Silicic acid anhydride, synthetic aluminum silicate, lactose, corn starch, crystalline cellulose and the like), binder (carboxymethyl cellulose, pregelatinized starch and the like), and other flavoring agents, sweeteners, colorants and the like can be contained.

Liquid formulations include aqueous or oily suspensions,
It may be a solution, syrup, or the like, or may be a dried product that can be redissolved in an appropriate vehicle before use. Such liquid formulations are commonly used emulsifiers.
(Lecithin, sorbitan monooleate, etc.), emulsification aid
(Sorbit syrup, methyl cellulose, gelatin
Etc.), non-aqueous vehicles (coconut oil, peanut oil, etc.),
In addition, an antioxidant, a coloring agent, a flavoring agent, etc. can be contained.

[0014]

The antibacterial periodontal agent according to the present invention is derived from a natural product, has an excellent antibacterial activity against periodontopathic bacteria, and is effective and safe for preventing and improving periodontal disease. Used.

[0015]

EXAMPLES The present invention will be shown in more detail with reference to Examples to specifically explain the effects of the present invention.

Example 1 and Comparative Example 1 Antibacterial test Strains [Bacteroides melaninogenikas] cryopreserved
( Bacteroides melaninogenicus ) GIFU 4637,
Fusobacterium nuculatum ( Fusobacterium nuc
leatum ) IID891, Bacteroides gingivalis
( Bacteroides gingivalis ) GAI7802] and GAM semi-fluid high-layer medium supplemented with hemin (Wako Pure Chemical Industries, Ltd.) 5 μg / ml and menadione (Sigma) 0.5 μg / ml
(Manufactured by Nissui Pharmaceutical Co., Ltd.) and cultured at 37 ° C. for 24 hours (Bacteroides gingivalis for 72 hours), and then hemin,
It was subcultured in GAM broth medium containing menadione (manufactured by Nissui Pharmaceutical Co., Ltd.) and anaerobically cultivated at 37 ° C. for 24 hours (using Mitsubishi Gas Chemical, Aneropack System). After culturing, the number of bacteria was adjusted to 10 ⁷ CFU / ml in GAM broth medium to prepare a test bacterial solution. Borneol is dissolved in DMSO and adjusted to the required concentration, then a membrane filter (0.45 μm, manufactured by German)
It was sterilized by filtration. Borneol dilution medium is prepared by GA
It was carried out by a two-fold dilution method using M broth medium. The test bacterial solution was inoculated into a liquid diluted medium (containing 10 µl of borneol at 6.25 to 100 ppm) in an amount of 90 µl and anaerobically cultured at 37 ° C for 24 hours (72 hours for Bacteroides gingivalis). Determined minimum inhibitory concentration
(MIC) was determined. Chlorhexidine hydrochloride (0.25 ~
For 8 ppm), the minimum inhibitory concentration (MIC) was determined in the same manner as in Example 1. (Comparative Example 1)

[0017]

[Table 1]

Claims (2)

[Claims] 1. An anti-periodontal disease agent comprising a crude drug extract obtained from one or more crude drugs selected from the group consisting of compressed sand, valerian root, lavender oil, rosemary oil and spiked lavender oil. . 2. An anti-periodontal disease drug containing borneol as an active ingredient.